Herpes zoster, commonly known as shingles, is a viral infection caused by the reactivation of the varicella-zoster virus (VZV), which also causes chickenpox. Pharmaceutical companies may develop antiviral medications and vaccines to manage or prevent herpes zoster.
Latest Herpes Zoster Companies Update
Nov 2023: Astellas Pharma Inc. and Propella Therapeutics, Inc. declared they had entered into a merger agreement wherein Astellas would purchase Propella through a U.S. subsidiary. A privately held biopharmaceutical business, Propella, developed novel oncology medications by utilizing a fully owned, patented platform that blends medicinal chemistry and lymphatic targeting. Astellas will obtain PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis blocker that Propella is developing to treat prostate cancer, as part of the acquisition of Propella. After intramuscular injection, PRL-02, a novel, long-acting prodrug* of abiraterone, is anticipated to reach high concentrations in target tissues where the active component, abiraterone, is constantly released. Due to increased CYP17 lyase, PRL-02 may offer better efficacy and safety than current therapy. PRL-02 is in a Phase 1 clinical trial and is expected to enter Phase 2a clinical trials in 2024.
Sep 2023: The Center for Drug Evaluation of China's National Medical Products Administration has received an application from the South Korean clinical-stage biotech business AriBio Co. for Phase 3 clinical trials on the anti-Alzheimer's candidate treatment AR1001. An estimated 100–150 participants will undergo testing on AR1001 in China as part of AriBio's ongoing Phase 3 Polaris-AD clinical trials involving 1,250 participants globally.
Herpes Zoster Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)